Journal article

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer

Abstract:: Background

Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expression ≥ 50%, either alone or in combination with chemotherapy when PD‐L1 expression is less than 50%. Atezolizumab (PD‐L1 inhibitor) has also been approved in combination w...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Ferrara, R., Imbimbo, M., Malouf, R., Paget-Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020). Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. Cochrane Database of Systematic Reviews, 2020(12).

MLA Style

Ferrara, R., et al. “Single or Combined Immune Checkpoint Inhibitors Compared to First‐Line Platinum‐Based Chemotherapy with or without Bevacizumab for People with Advanced Non‐Small Cell Lung Cancer.” Cochrane Database of Systematic Reviews, vol. 2020, no. 12, Cochrane Collaboration, 2020.

Chicago Style

Ferrara, R, M Imbimbo, R Malouf, S Paget-Bailly, F Calais, C Marchal, and V Westeel. 2020. “Single or Combined Immune Checkpoint Inhibitors Compared to First‐Line Platinum‐Based Chemotherapy with or without Bevacizumab for People with Advanced Non‐Small Cell Lung Cancer.” Cochrane Database of Systematic Reviews 2020 (12).
Share
Print

Access Document

Files:: Ferrara_et_al_2020_Single_or_combined.pdf

(Preview, Version of record, 1.0MB, Terms of use)

Publisher copy:: 10.1002/14651858.cd013257.pub2

Authors

+ Ferrara, R More by this author

Role:: Author

+ Imbimbo, M More by this author

Role:: Author

+ Malouf, R More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: NPEU
Role:: Author

+ Paget-Bailly, S More by this author

Role:: Author

+ Calais, F More by this author

Role:: Author

More authors...

Publisher:: Cochrane Collaboration
Journal:: Cochrane Database of Systematic Reviews More from this journal
Volume:: 2020
Issue:: 12
Article number:: CD013257
Publication date:: 2020-12-14
DOI:: 10.1002/14651858.cd013257.pub2
EISSN:: 1469-493X
Pmid:: 33316104

Language:: English
Keywords:: FFR
Pubs id:: 1150733
Local pid:: pubs:1150733
Deposit date:: 2021-06-01

Terms of use

Copyright holder:: Cochrane Collaboration
Copyright date:: 2020
Rights statement:: Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP